Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 µM. Bohemine is structurally similar to Olomoucine and Roscovitine.
CAS Number: 189232-42-6
Molecular Weight: 340.42
Chemical Name: 3-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: Soluble in DMSO, not in water
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥360 days if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
Bohemine (0-30 µM; 72 hours; ME-750 cells) treatment inhibits cell growth. Addition of Bohemine at concentrations in the range of 1-10 µM results in a short-term arrest of growth and of monoclonal antibody production. The short-term suppression of cell functions is followed by a significant temporary increase of specific growth rate and of specific production rate. Hybridoma cells are retarded both at the G1/S boundary and at the G2/M boundary, depending on Bohemine (0-30 µM) concentration. T-lymphoblastic cell line CEM is treated by Bohemine, five proteins are found to be downregulated, namely α-enolase, triosephosphate isomerase, initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins play significant roles in glycolysis, proteosynthesis, and in cytoskeleton rearrangement. Bohemine inhibits growth of human tumor cell lines with an IC50 of 27 µM.
Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment shows Cmax is 72, 308 nM, observed clearance is 0.23 L/h and T1/2 is 1.39 h.
- Novakova O, Liskova B, Vystrcilova J, Suchankova T, Vrana O, Starha P, Travnicek Z, Brabec V. Conformation and recognition of DNA damaged by antitumor cis-dichlorido platinum(II) complex of CDK inhibitor bohemine. Eur J Med Chem. 2014 May 6;78:54-64. doi: 10.1016/j.ejmech.2014.03.041. Epub 2014 Mar 15. PubMed PMID: 24675180.
- Liskova B, Zerzankova L, Novakova O, Kostrhunova H, Travnicek Z, Brabec V. Cellular response to antitumor cis-Dichlorido platinum(II) complexes of CDK inhibitor Bohemine and its analogues. Chem Res Toxicol. 2012 Feb 20;25(2):500-9. doi: 10.1021/tx200525n. Epub 2012 Feb 1. PubMed PMID: 22250642.
- Kovarova H, Halada P, Man P, Dzubak P, Hajduch M. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PubMed PMID: 12625783.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.